(Circulation. 1997;96:128-136.)
© 1997 American Heart Association, Inc.
Articles |
From the Centro Cuore Columbus (I.M., C. Di M., B.R., L. Di F., G.M., A.C.), Milan, Italy; Lenox Hill Hospital (J.M.), New York, NY; and the Department of Cardiology, University of California (J.T.), Irvine.
Correspondence to Antonio Colombo, MD, Centro Cuore Columbus, Via M. Buonarotti 48, 20145 Milan, Italy.
| Abstract |
|---|
|
|
|---|
Methods and Results Seventy-five consecutive patients with 106 lesions had rotablation prior to coronary stenting. Intravascular ultrasoundguided stenting was used without subsequent anticoagulation in 93% of patients. Procedural success was achieved in 93.4% of lesions. Acute stent thrombosis occurred in two lesions (1.9%), and subacute stent thrombosis in one lesion (0.9%). Angiographic follow-up was performed in 82.5% of lesions at 4.6±1.9 months with an angiographic restenosis rate of 22.5%. Clinical follow-up was performed in all patients at 6.4±3 months; target lesion revascularization was needed in 18% of lesions, Q-wave myocardial infarction occurred in 1.3%, coronary bypass surgery in 4.0%, and death in 1.3%.
Conclusions Optimal coronary stenting after rotablation in calcified and complex lesions can be performed with a high success rate, an acceptable rate of procedural complications, and a low rate of stent thrombosis. This approach was associated with a low incidence of angiographic restenosis compared with results usually obtained with other interventional strategies in calcified and complex lesion subsets.
Key Words: stents balloon calcium
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Rotational Atherectomy
Rotablation was performed14 by using two general
approaches: "facilitated expansion," which uses a single burr
with a small burr-to-artery ratio with the intention of altering the
plaque structure to allow better balloon expansion, and
"debulking," which uses progressively larger burrs to decrease
plaque mass. The decision concerning which strategy to employ was made
by the operator at the time of the intervention. Rotablation was almost
always started with a 1.5- or 1.75-mm burr. Care was taken to avoid
long passes. Verapamil, nitroglycerin, and
pauses of rotablation runs were used to control any slow flow occurring
during or after rotablation.
Stent Implantation Procedure
Intracoronary stenting was
performed11 18 19 in 82 lesions by using the Palmaz-Schatz
stent (Johnson & Johnson Interventional Systems). Other stents included
the Gianturco-Roubin stent (Cook Inc; 5 lesions), the Wiktor stent
(Medtronic Interventional Vascular; 2 lesions), the AVE stent (Applied
Vascular Engineering Inc; 2 lesions), the Wallstent (Schneider; 9
lesions), and a combination of the Palmaz-Schatz stent and other stents
(6 lesions). After stent implantation, angiographic optimization was
performed to achieve an acceptable angiographic result with <20%
residual stenosis by visual estimate. During the period of this
study, optimal stent deployment by IVUS was defined by (1) complete
apposition of the stent to the vessel wall, (2) symmetrical expansion
as defined by an SI >0.7, and (3) minimum intrastent CSA >90% of the
distal reference lumen CSA.
Angiographic Analysis
Coronary angiography was done in a routine manner.
Angiographic measurements were performed by an experienced angiographer
blinded to the IVUS measurements who used digital electronic calipers
(Brown and Sharp) and an optically magnified image in the view that
showed the most severe narrowing. Digital calipers correlate closely
with computer-assisted methods.20 Several angiographic
indexes were derived: acute gain (postprocedure MLD minus preprocedure
MLD), late loss (postprocedure MLD minus MLD at follow-up), and loss
index (late loss divided by acute gain). Lesions were classified
according to the modified American College of
CardiologyAmerican Heart Association
classification.21 Long lesions were defined as a single
continuous narrowing >15 mm in length.
IVUS Equipment and Measurements
From March 1993 until November 1993 a 3.9F monorail system
with a 25-MHz transducer-tipped catheter (Interpret Catheter,
InterTherapy/CVIS) was used. A cardiovascular imaging
system with a 2.9F catheter was used after November 1993. Validation of
quantitative measurements and pathological correlation has been
reported.22 23 Online quantitative measurements were
performed during the procedure. The cross section with the smallest
lumen area inside the stent was selected for measurements for each pass
of the IVUS catheter. The minimum and maximum lumen diameters were
recorded, and an SI was derived (SI=MLD divided by maximal lumen
diameter). SIs <1 indicate a progressive increase in lumen asymmetry.
Measurements in the reference segment were obtained proximal and distal
to the stented segment in the closest most normalappearing segments.
The average reference vessel and lumen CSAs were calculated as the
average of the proximal and distal reference vessel and lumen CSAs,
respectively. No vessel size measurements were performed at the site of
narrowing (except for lumen dimensions) because the shadowing induced
by calcifications and stent struts limit the ability to define the
vessel. Interobserver and intraobserver reproducibility of MLD and
lumen CSA measurements have been documented.11
Prerotablation IVUS was performed in 36 lesions (34%). The general
approach was not to perform preintervention IVUS when calcifications
were seen on fluoroscopy at or near the lesion where the operator had
already planned to perform rotablation. IVUS was performed in 21
lesions after balloon predilatation because of suboptimal balloon
expansion and in 15 lesions because calcification was strongly
suspected. Calcified lesions that underwent rotablation were identified
as subintimal (superficial) echo-dense structures producing external
shadowing and with an arc
180°.
Procedural Success and Clinical Events
Angiographic success was defined as a final angiographic
residual diameter stenosis of <20%. Clinical events were
defined as follows: death, any death irrespective of cause; Q-wave MI,
by the presence of new Q waves (>0.4 s) on an ECG in conjunction with
elevation in creatine kinase to greater than twice normal; nonQ-wave
MI, by an elevation of cardiac enzymes to greater than twice normal
without new pathological Q waves. Emergency CBS involved transfer of
the patient from the catheterization laboratory to the
operating room immediately or within 24 hours of the procedure.
Elective CBS was defined as bypass surgery performed >24 hours after a
stent procedure for procedural failure in the absence of
ischemia. Acute thrombosis was defined as angiographically
documented occlusion at the stent site occurring within 24 hours of the
stent procedure. Subacute thrombosis events were angiographically
documented occlusions at the stent site occurring beyond 24 hours of
the stent procedure. Repeat angioplasty was defined as angioplasty
performed for restenosis.
Follow-Up
Short term follow-up was performed by a telephone conversation
with the patient at 2 months. Late follow-up was planned at 6 months
unless patients had recurrent symptoms or an event requiring earlier
angiographic follow-up.
Statistics
Statistical analysis was performed by using the SPSS
statistical package. Continuous normally distributed data are expressed
as mean±SD. Comparison of continuous variables between groups was
performed by using an unpaired student's t test. Subgroup
comparison of categorical variables was performed by using
2 analysis. Differences were considered
significant at P<.05. Logistic regression analysis
was used to study predictors of angiographic restenosis and
target lesion revascularization. All relevant
procedural, angiographic, and IVUS variables were entered into the
analysis. A forward conditional stepwise selection model was
used. Removal testing was based on the probability of the
likelihood-ratio statistic based on conditional parameter
estimates.
| Results |
|---|
|
|
|---|
|
|
Indications for Rotablation and Stenting and Procedural
Characteristics
Indications for rotablation were calcified (70%) and long (10%)
lesions. Other indications (20%) for rotablation included suboptimal
balloon expansion and inability to pass an IVUS catheter or a balloon
across the lesion. Indications for stenting were elective (69%),
suboptimal result after rotablation (12%), restenotic lesions
(9%), threatened closure (7%), and chronic total occlusions (3%).
Rotablation was performed in the majority of lesions as the initial
procedure prior to dilatation (80%). A single burr was used in 64
lesions (60%), two burrs in 35 lesions (33%), and three burrs in 7
lesions (7%). The final burr size was 1.85±0.27 mm, with a
burr-to-vessel ratio of 0.61±0.12. An average of 1.7±1 (range, 0.5 to
5) stents per lesion were implanted. The final balloon-to-vessel ratio
was 1.17±0.19, with a maximal balloon inflation pressure of 16±3
atm.
Angiographic and IVUS Analysis
Of the total patient cohort, 5 patients (6.7%) had unsuccessful
stent implantation; they were excluded from this analysis.
Baseline and postprocedural angiographic measurements are shown in
Table 3
. IVUS following successful stent implantation
was performed in 63 of the remaining 70 patients (90%) with 88 lesions
(89%). It was not attempted in 4 patients (6%), and it was
unsuccessful in 3 patients (4%). A suboptimal final IVUS result was
left in 1 patient (2%) with 2 lesions. A final optimal ultrasound was
achieved in 62 patients with 86 lesions (87% of lesions with
successful angiographic stent implantation).
|
Postprocedural intrastent minimum lumen CSA was 7.15±2.15 mm2, which is similar to the average reference lumen CSA of 7.03±2.20 mm2 (P=.38) and larger than the distal reference lumen CSA of 6.32±2.54 mm2 (P=.002). Postprocedural intrastent MLD was 2.74±0.51 mm, mean SI achieved was 0.87±0.11, and 91% of lesions had anSI >0.7.
Procedural Success, Complications, and Short-Term Outcome
Initial stent implantation was angiographically successful in 70
patients (93.3%) with 99 lesions (93.4%). The stent implantation
procedure was unsuccessful in 5 patients (6.6%), all of whom had
procedural complications (Table 4
). One patient had a
guiding catheterinduced left main dissection that led to the
patient's death; a second had acute stent thrombosis and had to
undergo emergency bypass surgery; a third had coronary vessel
rupture during stent optimization; the last 2 patients had false lumen
stenting of a chronic total occlusion with subsequent no flow. These
two patients underwent emergency bypass surgery.
|
In-hospital events occurred in 3 patients (4%; Table 4
). One patient
had acute stent thrombosis 12 hours after the procedure and underwent
emergency PTCA successfully. A second patient, who had slow flow
postprocedure, had elective CBS in 2 days. A third patient had
subacute stent thrombosis 4 days postprocedure and underwent
emergency PTCA and further stenting successfully without further
events.
Short-term follow-up was available in all patients at 2 months (Table 4
.) One sudden death occurred 7 days after a second stent procedure
performed without prior rotablation at the ostium of the left
circumflex artery. Stent thrombosis seems the most likely cause of
death in this patient. However, it is unclear whether this event
occurred in the lesion treated with rotablation prior to stenting or in
the lesion treated only with stenting.
Late Events
Long-term follow-up was obtained in all patients at a mean of
6.4±3 months (Table 4
). Late events occurred in 18 patients (24%).
The majority of these events were due to repeat angioplasty for
restenosis, which was performed in 13 patients (17%) on 19
lesions (18%). Three patients (4.0%) underwent elective CBS, 2 for
target lesion revascularization and 1 for left main
dissection during a follow-up angiogram at another hospital. There was
one sudden death (1.3%) 5.5 months after the procedure and 1 month
after a follow-up angiogram that showed no restenosis. One
patient (1.3%) had a nonQ-wave MI after a repeat angioplasty for
restenosis.
Antiplatelet and Anticoagulation Therapy
Sixty-five of the 70 patients (93%) were treated with
antiplatelet medications: ticlopidine and aspirin in 62 patients
(89%) and aspirin alone in 3 (4%); none of these patients received
additional anticoagulation. A total of 5 patients (7%) were treated
with a standard anticoagulation regimen of heparin, warfarin for 2
months, and aspirin indefinitely. This group included 2 patients with
optimal IVUS criteria: 1 had severe slow flow after the procedure, and
the second underwent stenting of the ostial left anterior descending
artery and the ostium of the circumflex artery (left main equivalent).
A third patient had suboptimal final IVUS, a fourth had an unsuccessful
IVUS examination, and in the fifth patient IVUS was not attempted.
Incidence and Predictors of Restenosis and Target
Lesion Revascularization
Fifty-four of 68 eligible patients (79.4%) with 80 lesions
(82.5%) had angiographic follow-up at 4.6±1.9 (range, 2.1 to 13.3)
months. The overall incidence of restenosis was 22.5% on a
per-lesion basis. Factors associated with restenosis are listed
in Table 5
. All these factors were entered into a
stepwise logistic regression analysis model to study their
predictive value for angiographic restenosis and target lesion
revascularization; results are shown in Table 6
.
|
|
A Subgroup Analysis of Elective Palmaz-Schatz Stenting
After Rotablation
This subgroup included 53 patients (age, 61±11 years) with
71 lesions. Type B2 and C lesions were present in 77% of cases.
Angiographic proximal reference diameter was 3.24±0.51 mm; lesion
length was 10.37±7.44 mm. The presence of moderate to severe
calcifications was the indication for rotablation in 75% of lesions. A
single burr was used in 41 lesions (58%), two burrs in 25 lesions
(35%), and three burrs in 5 lesions (7%); the largest burr-to-vessel
ratio was 0.6±0.1. Stenting was elective in all lesions (including 8
restenotic lesions and 2 chronic total occlusions), with 1.9±1.1
stents per lesion, a balloon-to-vessel ratio of 1.15±0.18, and maximal
inflation pressure of 16±3 atm. Procedural success was achieved in
97% of cases; postprocedural MLD was 3.25±0.55 mm (-3±13%
residual diameter stenosis). Acute stent thrombosis occurred in
1 lesion (1.4%) and subacute stent thrombosis in 1 lesion (1.4%).
Angiographic follow-up was performed in 57 lesions (85% of eligible
lesions) at 5.0±2.0 months. Angiographic restenosis occurred
in 13 lesions (23%). Clinical follow-up was performed in all patients
at 6.5±2.5 months; 12 lesions (17%) needed repeat angioplasty.
Multivariate predictors of angiographic
restenosis and target lesion
revascularization in this subgroup are shown in
Table 6
.
| Discussion |
|---|
|
|
|---|
It is generally accepted that appropriate stent expansion is a crucial
factor in preventing stent thrombosis11 12 and possibly
decreasing the incidence of restenosis.13 27
Published data on coronary stenting alone in calcified and
complex lesions are limited. Our own experience in this regard is only
anecdotal and not based on a randomized protocol. Table 7
compares elective Palmaz-Schatz stenting for calcified
lesions with and without rotablation over the same time period.
Stenting alone was used for shorter lesions, which require fewer
stents, in larger vessels. Stents were expanded by using a high
balloon-inflation pressure with a similar balloon-to-vessel ratio.
After adjusting for vessel size, the rotablation-stent group had a
lower residual angiographic percent diameter stenosis and a
higher ratio of minimal stent CSAtovessel CSA and a higher SI. In
addition, 3 of 41 patients (7%) in the stent-alone group required
emergency bypass surgery because of occlusive dissections after
stenting. These data are consistent with prior observations
suggesting that even balloon pressures >20 atm may be insufficient to
overcome the limitations imposed by a severely calcified plaque, and
attempts to obtain full expansion of a stent may cause vessel rupture
instead of further enlarging the stent. Fig 1
shows
images obtained with a 0.018-inch imaging guide wire (CVIS, Boston
Scientific, Inc) positioned inside a balloon inflated at 24 atm at the
site of an incomplete stent expansion in a calcified lesion not treated
with rotablation. It is clear from these images that high-pressure
inflation in resistant lesions may be insufficient to achieve
nominal balloon size, despite the apparent angiographic complete
balloon expansion. Others18 have shown that the use of an
oversized balloon to overcome this problem is associated with
significant vessel complications such as vessel rupture. For these
reasons we feel that the best approach to facilitate stent expansion in
a calcified lesion is to modify vessel wall compliance by partial
removal of the plaque using rotablation, as shown in Fig 2
.
|
|
|
Procedural Success and Complications
Successful outcome of a catheter-based coronary
intervention depends on several factors, including operator experience,
patient's age, ventricular function, vessel size, and
lesion characteristics, especially calcifications and lesion
length.4 5 6 The current study describes a success rate of
93.4%, using an angiographically defined success of <20% residual
stenosis. In this study, IVUS examination poststenting
demonstrated that the combined approach clearly accomplished optimal
stent deployment by eliminating the problem of asymmetrical and
incomplete stent expansion (Fig 3
). It is important to
consider that 36% of vessels were <3.0 mm in size, 71% of
lesions were calcified, 16% of lesions were longer than 15 mm,
and lesion types B2 or C were present in 71% of cases. Procedural
complications occurred in 6.6% of patients: death in 1.3%, emergency
CBS in 4%, Q-wave MI in 1.3%, and nonQ-wave MI in 6.7%. Mintz et
al28 have reported a series of 88 patients with large
vessels (>3.0 mm) and calcified lesions who underwent stenting
postrotablation without procedural and in-hospital complications;
6-month angiographic and clinical follow-up results were not available.
In studies using rotablation and PTCA, Warth et al24
report a success rate of 95% with major procedural complications in
3% (1.9% to 4.5%); Ellis et al25 report a success rate
of 93.5% and major procedural complications in 3.4%; and Henson et
al26 report procedural success in 94% (age >70 years)
and 88% (age >80 years). In all these studies procedural success was
defined as a final angiographic residual stenosis of <50% of
the reference diameter. In addition, lesion complexity, especially
calcifications, ranged from 32% to 58%, and the presence of type B2
or C lesions ranged from 36% to 60%. In light of this
heterogeneity in vessel size and prevalence of complex
lesions and in the definition of success used in other studies, it is
difficult to make a direct matched comparison. However, it becomes
clear that the procedural success and complication rate reported in
this study remain acceptable.
|
Slow-Flow Phenomenon and Stent Thrombosis
It has been speculated that coronary stenting
postrotablation might increase the risk of stent thrombosis
secondary to the slow-flow phenomenon. In the present study
refractory slow flow (without optimal response to intracoronary
nitroglycerin and verapamil) occurred in 1
lesion (0.9%), and thrombus formation postrotablation occurred in 1
lesion (0.9%). This is comparable with other studies. Warth et
al24 report slow flow in 1.2% (0.5% to 2.3%) of
patients and thrombus formation in 1.6% (0.8% to 2.8%), Ellis et
al25 report slow flow in 5.1% of cases, and Piana et
al29 report a 2% incidence of no reflow.
When a stent was deployed after refractory slow flow, compromised flow persisted, and the patient had to undergo elective bypass surgery within 2 days. The second case of acute stent thrombosis occurred in a patient with acute ischemic syndrome, where a thrombus may have played a role. This brings the incidence of acute stent thrombosis to 1.9%. Subacute stent thrombosis occurred in 1 lesion (0.9%), an incidence that is identical to our earlier experience with stenting without anticoagulation and without adjunct rotablation.11 In addition, this rate of stent thrombosis compares favorably with that reported by other investigators with coronary stenting alone. Barragan et al30 and Morice et al31 report stent thrombosis in 4.2% and 1.6% of patients, respectively.
The unique and new aspect in the present study is the rather high incidence of acute stent thrombosis. A preliminary conclusion concerning the issue of stent thrombosis and rotablation can be drawn: the incidence of stent thrombosis after rotablation remains low provided attention is paid to avoid the slow-flow phenomenon by following a careful technique and by avoiding stenting in the event that slow flow persists. In addition, the examination of postprocedural stent MLD and CSA suggests a positive role for rotablation through facilitating stent expansion and optimal deployment.
Incidence and Predictors of Restenosis
Restenosis after PTCA is related to clinical and
angiographic factors such as vessel size, lesion length, lesion
calcifications, and postprocedural residual
stenosis.5 6 7 32 Restenosis rates after
rotablation range from 37% to 51%.24 26 33 In this study
the restenosis rate was 22.5%, with angiographic follow-up
accomplished in 82.5% of lesions. At present, there is no
published data on angiographic restenosis with coronary
stenting in a similar patient population, and our results compare
favorably with restenosis rates of coronary stenting in
simple lesions.2 3 This may suggest that the combined
approach of stenting postrotablation in calcified and complex lesions
transforms lesions with a high preintervention probability of
restenosis to a lower risk category. This concept is further
supported by the fact that the loss index in this population was
0.53±0.48, which is similar to that reported poststenting alone of
noncalcified lesions. This suggests that rotablation prior to stenting
does not increase late loss compared with stenting alone.
Stent type and indication did not differ between the restenosis and no-restenosis groups. However, the number of stent types other than the Palmaz-Schatz and the number of lesions undergoing bailout stenting were too small to draw firm conclusions in regard to their contribution to the restenotic process. Logistic regression analysis showed that the only predictors of restenosis in the total cohort and in the subgroup with elective Palmaz-Schatz stenting were small postprocedural MLD by IVUS (which also predicted the need for repeat angioplasty) and lesion length. These findings are consistent with prior studies.13 27 34 It is of interest to note that the MLD by IVUS was a stronger predictor of restenosis than angiographic measurements, which might stem from the fact that IVUS better defines true lumen dimensions than does angiography.
Study Limitations
Limitations include the fact that this study was a retrospective
analysis; no routine preintervention IVUSs were performed to
predefine inclusion parameters; and several stent types
were used for different indications, which prohibits drawing
conclusions in regard to the effect of specific stent type on outcome.
Despite these shortcomings, the uniqueness of this population defines a
subgroup in which previous interventions have been highly unsuccessful
or associated with a very high restenosis rate.
Conclusions
On the basis of our observations, we conclude that rotablation in
selected calcified and complex lesions allows optimal coronary
stenting to be performed safely without anticoagulation. This approach
may also reduce angiographic restenosis and target lesion
revascularization compared with the results
typically obtained by other catheter-based coronary
interventions in similar types of lesions.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received July 11, 1996; revision received December 17, 1996; accepted January 9, 1997.
| References |
|---|
|
|
|---|
2.
Fischman D, Leon M, Baim D, Schatz R, Savage M, Penn
I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond
D, Teirstein P, Fish D, Colombo A, Brinker J, Moses J, Shaknovich A,
Hirshfeld J, Baily S, Ellis S, Rake R, Goldberg S. A randomized
comparison of coronary stent placement and balloon angioplasty
in the treatment of coronary artery disease.
N Engl J Med. 1994;331:496-501.
3.
Serruys P, Jaegere P, Kiemeneij F, Macaya C,
Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P,
Belardi J, Sigwart U, Colombo A, Goy JJ, Heuvel P, Delcan J, Morel
M. A comparison of balloon expandable stent implantation with
balloon angioplasty in patients with coronary artery
disease. N Engl J Med. 1994;331:489-495.
4. Sharma S, Israel D, Kamean J, Bodian C, Ambrose J. Clinical, angiographic, and procedural determinants of major and minor coronary dissections during angioplasty. Am Heart J. 1993;126:39-47.[Medline] [Order article via Infotrieve]
5. Alfonso F, Macaya C, Iniguez A, Fernandez Ortiz A, Zarco P. Coronary angioplasty of calcified lesions. Rev Esp Cardiol. 1990;43:231-238.[Medline] [Order article via Infotrieve]
6. Myeler R, Shaw R, Stertzer S, Hecht HS, Ryan C, Rosenblum J, Cumberland DC, Murphy MC, Hansell HN, Hidalgo B. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol. 1992;19:1641-1652.[Abstract]
7. Ellis S, Roubin G, King SI, Douglas JJ, Cox W. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty. Am J Cardiol. 1989;63:30-34.[Medline] [Order article via Infotrieve]
8. Alfonso F, Macaya C, Goicolea J, Hernandez R, Segovia J, Zamorano J, Banvelos C, Zarco P. Determinants of coronary compliance in patients with coronary artery disease: an intravascular ultrasound study. J Am Coll Cardiol. 1994;23:879-884.[Abstract]
9.
Fitzgerald P, Ports T, Yock P. Contribution of
localized calcium deposits to dissection after angioplasty: an
observational study using intravascular ultrasound.
Circulation. 1992;86:64-70.
10. Fitzgerald P, for the STRUT Registry Investigators. Lesion composition impacts size and symmetry of stent expansion: initial report from the strut registry. J Am Coll Cardiol. February 1995;49A(special issue):902-2. Abstract.
11.
Colombo A, Hall P, Nakamura S, Almagor Y, Maiello
L, Martini G, Gaglione A, Goldberg SL, Tobis J.
Intracoronary stenting without anticoagulation accomplished
with intravascular ultrasound guidance. Circulation. 1995;91:1676-1688.
12. Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6-12.[Abstract]
13.
Kuntz R, Safian R, Carrozza J, Fischman R, Mansour M,
Baim D. The importance of acute luminal diameter in determining
restenosis after coronary atherectomy or
stenting. Circulation. 1992;86:1827-1835.
14. O'Neill W. Mechanical rotational atherectomy. Am J Cardiol. 1992;69:12F-18F.[Medline] [Order article via Infotrieve]
15. Kovach JA, Mintz GS, Pichard AD, Kent KM, Popma JJ, Satler LF, Leon MB. Sequential intravascular ultrasound characterization of the mechanisms of rotational atherectomy and adjunct balloon angioplasty. J Am Coll Cardiol. 1993;22:1024-1032.[Abstract]
16. Stertzer S, Pomerantsez E, Shaw R, Boucher R, Millhouse F, Zipkin R, Hidalgo B, Murphy M, Hansell H, Myler R. Comparative study of the angiographic morphology of coronary artery lesions treated with PTCA, directional coronary atherectomy, or high speed rotational ablation. Cathet Cardiovasc Diagn. 1994;33:1-9.[Medline] [Order article via Infotrieve]
17. Stertzer S, Rosenblum J, Shaw R, Sugeng I, Hidalgo B, Ryan C, Hansell H, Murphy M, Myler R. Coronary rotational ablation: initial experience in 302 procedures. J Am Coll Cardiol. 1993;21:287-295.[Abstract]
18.
Nakamura S, Colombo A, Gaglione S, Almagor Y, Goldberg
SL, Maiello ML, Finci L, Tobis JM. Intracoronary
ultrasound observations during stent implantation.
Circulation. 1994;89:2026-2034.
19. Moussa I, Di Mario C, Di Francesco L, Reimers B, Blengino S, Colombo A. Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Am J Cardiol. 1996;78(suppl 3A):13-17.
20. Scoblianco DP, Brown G, Mitten S. A new digital electronic caliper for measurement of coronary arterial stenosis: a comparison with visual and computer assisted measurements. Am J Cardiol. 1984;53:689-693.[Medline] [Order article via Infotrieve]
21.
Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III,
Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL Jr. Guidelines
for percutaneous transluminal coronary
angioplasty: a report of the American College of
Cardiology/American Heart Association Task Force on
Assessment of Diagnostic and Therapeutic
Cardiovascular Procedures. Circulation. 1988;78:486-502.
22.
Tobis JM, Mallory J, Mahon D, Lehman K, Zalesky P,
Griffith J, Henry WL. Intravascular ultrasound imaging of human
coronary arteries in vivo: analysis of tissue
characteristics with comparison to in vitro histologic
specimens. Circulation. 1991;83:913-926.
23. Nishimura RA, Edwards WD, Warnes CA, Reeder GS, Holmes DR Jr, Tajik AJ, Yock PJ. Intravascular ultrasound imaging: in vitro validation and pathologic correlation. J Am Coll Cardiol. 1990;16:145-154.[Abstract]
24. Warth D, Leon M, O'Neill W, Zacca N, Polissar N, Buchbinder M. Rotational atherectomy multicenter registry: acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol. 1994;24:641-648.[Abstract]
25.
Ellis S, Popma J, Buchbinder M, Franco I, Leon M,
Kent K, Pichard A, Satler L, Topol E, Whitlow P. Relation of
clinical presentation, stenosis morphology, and
operator technique to the procedural results of rotational
atherectomyfacilitated angioplasty. Circulation. 1994;89:882-892.
26. Henson K, Popma J, Leon M, Kent K, Satler L, Mintz G, Keller M, Deible R, Pichard A. Comparison of results of rotational coronary atherectomy in three age groups (<70, 70-79, and >80 years). Am J Cardiol. 1993;71:862-864.[Medline] [Order article via Infotrieve]
27. Carrozza J, Kuntz R, Schatz R, Leon M, Goldberg S, Savage M, Fischman D, Senerchia C, Diver D, Baim D. Inter-series differences in the restenosis rate of Palmaz-Schatz coronary stent placement: differences in demographics and post-procedure lumen diameter. Cathet Cardiovasc Diagn. 1994;31:173-178.[Medline] [Order article via Infotrieve]
28. Mintz G, Dussaillant G, Wong C, Pichard A, Satler L, Bucher T, Leon M. Rotational atherectomy followed by adjunct stents: the preferred therapy for calcified lesions in large vessels? Circulation. 1995;92(suppl I):I-329. Abstract.
29.
Piana R, Paik J, Moscucci M, Cohen D, Gibson M,
Kugelmass A, Carozza J, Kuntz R, Baim D. Incidence and treatment
of "no reflow' after percutaneous coronary
intervention. Circulation. 1994;89:2514-2518.
30. Barragan P, Sainsous J, Silvestri M, Bouvier J, Comet B, Simeoni J, Charmasson C, Bremondy M. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting. Cathet Cardiovasc Diagn. 1994;32:133-138.[Medline] [Order article via Infotrieve]
31. Morice CM, Breton C, Amor M, Bunouf P, Cattan S, Eltchaninoff H, Henry M, Joly P, Livarek B, Pilliere R, Rioux P, Spaulding C, Zemour G. Coronary stenting without anticoagulant, without intravascular ultrasound: results of the French registry. Circulation. 1995;92(suppl I):I-796. Abstract.
32. Itoh A, Hall P, Maiello L, Blengino S, Finci L, Ferraro M, Martini G, Colombo A. Coronary stenting of long lesions (greater than 20 mm): a matched comparison of different stents. Circulation. 1995;92(suppl I):I-688. Abstract.
33.
Safian R, Niazi K, Strazeleski M, Lichtenberg A, May M,
Juran N, Freed M, Ramos R, Gangadharan V, Grines C, O'Neill W.
Detailed angiographic analysis of high-speed mechanical
rotational atherectomy in human coronary arteries.
Circulation. 1993;88:961-968.
34.
Ellis S, Savage M, Fischman D, Baim D, Leon M, Goldberg
S, Hirshfeld J, Cleman M, Teirstein P, Walker C, Bailey S, Buchbinder
M, Topol E, Schatz R. Restenosis after placement of
Palmaz-Schatz stents in coronary arteries.
Circulation. 1992;86:1836-1844.
This article has been cited by other articles:
![]() |
L. R Sajja, G. Mannam, B. R S Dandu, S. Pathuri, S. Sompalli, and A. Anjaneyulu Outcomes of Mitral Valve Repair for Chronic Ischemic Mitral Regurgitation Asian Cardiovasc Thorac Ann, January 1, 2009; 17(1): 29 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Di Mario and P. Barlis Optical Coherence Tomography: A New Tool to Detect Tissue Coverage in Drug-Eluting Stents J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 174 - 175. [Full Text] [PDF] |
||||
![]() |
S. Aziz, J. L Morris, R. A Perry, and R. H Stables Stent expansion: a combination of delivery balloon underexpansion and acute stent recoil reduces predicted stent diameter irrespective of reference vessel size Heart, December 1, 2007; 93(12): 1562 - 1566. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fukuoka, M. Nonaka, S. Masuyama, T. Shimamoto, K. Tambara, H. Yoshida, T. Ikeda, and M. Komeda Chordal "translocation" for functional mitral regurgitation with severe valve tenting: An effort to preserve left ventricular structure and function J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 1004 - 1011. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. K. Mishra, S. Mittal, P. Jaguri, and N. Trehan Coapsys Mitral Annuloplasty for Chronic Functional Ischemic Mitral Regurgitation: 1-Year Results Ann. Thorac. Surg., January 1, 2006; 81(1): 42 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Iakovou, L. Ge, and A. Colombo Contemporary Stent Treatment of Coronary Bifurcations J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1446 - 1455. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zamorano, L. P. de Isla, L. Oliveros, C. Almeria, J. L. Rodrigo, A. Aubele, J. Banchs, and C. Macaya Prognostic influence of mitral regurgitation prior to a first myocardial infarction Eur. Heart J., February 2, 2005; 26(4): 343 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Yu, M.-Y. Su, T.-Y. Liao, H.-H. Peng, F.-Y. Lin, and W.-Y. I. Tseng Functional mitral regurgitation in chronic ischemic coronary artery disease: Analysis of geometric alterations of mitral apparatus with magnetic resonance imaging J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 543 - 551. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kwon, D. Choi, S.-H. Choi, Bon Kwon Koo, Y. Jang, W.-H. Shim, and S.-Y. Cho Coronary Stenting After Rotational Atherectomy in Diffuse Lesions of the Small Coronary Artery: Comparison with Balloon Angioplasty Before Stenting Angiology, July 1, 2003; 54(4): 423 - 431. [Abstract] [PDF] |
||||
![]() |
A. Colombo, G. Stankovic, and J. W. Moses Selection of coronary stents J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1021 - 1033. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Rubenstein, L. C. Harrell, B. V. Sheynberg, H. Schunkert, H. Bazari, and I. F. Palacios Are Patients With Renal Failure Good Candidates for Percutaneous Coronary Revascularization in the New Device Era? Circulation, December 12, 2000; 102(24): 2966 - 2972. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Dill, U Dietz, C.W Hamm, R Kuchler, H.-J Rupprecht, M Haude, J Cyran, C Ozbek, K.-H Kuck, J Berger, et al. A randomized comparison of balloon angioplasty versus rotational atherectomy in complex coronary lesions (COBRA study) Eur. Heart J., November 1, 2000; 21(21): 1759 - 1766. [Abstract] [PDF] |
||||
![]() |
T. Akiyama, I. Moussa, B. Reimers, M. Ferraro, Y. Kobayashi, S. Blengino, L. Di Francesco, L. Finci, C. Di Mario, and A. Colombo Angiographic and clinical outcome following coronary stenting of small vessels: A comparison with coronary stenting of large vessels J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1610 - 1618. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bermejo, J. Botas, E. Garcia, J. Elizaga, J. Osende, J. Soriano, M. Abeytua, and J. L. Delcan Mechanisms of Residual Lumen Stenosis After High-Pressure Stent Implantation : A Quantitative Coronary Angiography and Intravascular Ultrasound Study Circulation, July 14, 1998; 98(2): 112 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Moussa, B. Reimers, J. Moses, C. Di Mario, L. Di Francesco, M. Ferraro, and A. Colombo Long-term Angiographic and Clinical Outcome of Patients Undergoing Multivessel Coronary Stenting Circulation, December 2, 1997; 96(11): 3873 - 3879. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |